Inova Fairfax Hospital for Children, Falls Church, VA, USA.
J Pediatr Gastroenterol Nutr. 2011 Feb;52(2):230-2. doi: 10.1097/MPG.0b013e3181f3d9ab.
Infliximab is frequently used to treat both inflammatory bowel disease (IBD) and psoriasis. We reviewed the medical records of 73 children with IBD receiving infliximab therapy and identified 6 (8%) cases of infliximab-induced psoriasis. Five (83%) had Crohn disease and 4 (67%) were girls. The psoriatic lesions appeared on the face (n = 5; 83%) and perineum (n = 1; 17%). A median of 13 doses were administered during a median duration of 21 months. All of the patients were continued on infliximab to maintain clinical remission of IBD. Educating children with IBD and their caregivers about this paradoxical phenomenon and periodic dermatology evaluation may promote patient care.
英夫利昔单抗常用于治疗炎症性肠病（IBD）和银屑病。我们回顾了 73 名接受英夫利昔单抗治疗的 IBD 患儿的病历，发现有 6 例（8%）英夫利昔单抗诱导的银屑病。其中 5 例（83%）患有克罗恩病，4 例（67%）为女孩。银屑病皮损出现在面部（n=5；83%）和会阴（n=1；17%）。在 21 个月的中位时间内给予中位数为 13 剂的英夫利昔单抗。所有患者均继续使用英夫利昔单抗以维持 IBD 的临床缓解。教育 IBD 患儿及其照顾者了解这种矛盾现象并进行定期皮肤科评估可能会促进患者护理。
